The IMpower-132 trial for non small cell lung cancer

ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma

Keynote lecture: Mutation signatures and targeting the DNA damage response

Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma

COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma

Latest advances in treatment for ALK positive NSCLC

The case for biosimilars

Highlights in early non-metastatic NSCLC and thoracic tumours

Highlights in SCLC from ESMO 2018

Safety analysis of entrectinib for NTRK fusion tumours

TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer

ASCEND-8: safety data of ceritinib with or without food in NSCLC